TY - JOUR
T1 - Analysis of micrometastatic disease in sentinel lymph nodes from resectable colon cancer
T2 - Results of cancer and leukemia group B trial 80001
AU - Redston, Mark
AU - Compton, Carolyn C.
AU - Miedema, Brent W.
AU - Niedzwiecki, Donna
AU - Dowell, Jeannette M.
AU - Jewell, Scott D.
AU - Fleshman, James M.
AU - Bem, Jiri
AU - Mayer, Robert J.
AU - Bertagnolli, Monica M.
PY - 2006/2/20
Y1 - 2006/2/20
N2 - Purpose: To determine whether sentinel lymph node (LN) sampling (SLNS) could reduce the number of nodes required to characterize micrometastatic disease (MMD) in patients with potentially curable colon cancer. Patients and Methods: Cancer and Leukemia Group B 80001 was a study to determine whether SLNS could identify a subset of LNs that predicted the status of the nodal basin for resectable colon cancer and, therefore, could be extensively evaluated for the presence of micrometastases. Patients enrolled onto this study underwent SLNS after injection of 1% isosulfan blue, and both sentinel nodes (SNs) and non-SNs obtained during primary tumor resection were sectioned at multiple levels and stained using anti-carcinoembryonic antigen and anticytokeratin antibodies. Results: Using standard histopathology, SNs failed to predict the presence of nodal disease in 13 (54%) of 24 node-positive patients. Immunostains were performed for patients whose LNs were negative by standard histopathology. Depending on the immunohistochemical criteria used to assign LN positivity, SN examination resulted in either an unacceptably high false-positive rate (20%) or a low sensitivity for detection of MMD (40%). Conclusion: By examining both SNs and non-SNs, this multi-institutional study showed that SNs did not accurately predict the presence of either conventionally defined nodal metastases or MMD. As a result, SLNS is not a useful technique for the study of MMD in patients with colon cancer.
AB - Purpose: To determine whether sentinel lymph node (LN) sampling (SLNS) could reduce the number of nodes required to characterize micrometastatic disease (MMD) in patients with potentially curable colon cancer. Patients and Methods: Cancer and Leukemia Group B 80001 was a study to determine whether SLNS could identify a subset of LNs that predicted the status of the nodal basin for resectable colon cancer and, therefore, could be extensively evaluated for the presence of micrometastases. Patients enrolled onto this study underwent SLNS after injection of 1% isosulfan blue, and both sentinel nodes (SNs) and non-SNs obtained during primary tumor resection were sectioned at multiple levels and stained using anti-carcinoembryonic antigen and anticytokeratin antibodies. Results: Using standard histopathology, SNs failed to predict the presence of nodal disease in 13 (54%) of 24 node-positive patients. Immunostains were performed for patients whose LNs were negative by standard histopathology. Depending on the immunohistochemical criteria used to assign LN positivity, SN examination resulted in either an unacceptably high false-positive rate (20%) or a low sensitivity for detection of MMD (40%). Conclusion: By examining both SNs and non-SNs, this multi-institutional study showed that SNs did not accurately predict the presence of either conventionally defined nodal metastases or MMD. As a result, SLNS is not a useful technique for the study of MMD in patients with colon cancer.
UR - http://www.scopus.com/inward/record.url?scp=33644915829&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644915829&partnerID=8YFLogxK
U2 - 10.1200/JCO.2005.03.6038
DO - 10.1200/JCO.2005.03.6038
M3 - Article
C2 - 16418493
AN - SCOPUS:33644915829
SN - 0732-183X
VL - 24
SP - 878
EP - 883
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 6
ER -